Historique
Auteur S. D. COMER
Documents disponibles écrits par cet auteur (15)
Ajouter le résultat à votre sélection Affiner la recherche![Are you thinking what I'm thinking? Defining what we mean by "polysubstance use" [Comment]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=86883)
A. M. BUNTING ; R. SHEARER ; A. N. LINDEN-CARMICHAEL ; A. R. WILLIAMS ; S. D. COMER ; M. CERDA ; J. LORVICK | 2024
Dans American Journal of Drug and Alcohol Abuse (Vol.50, n°1, January 2024) Article : PériodiqueThe rise in drug overdoses and harms associated with the use of more than one substance has led to increased use of the term "polysubstance use" among researchers, clinicians, and public health officials. However, the term retains no consistent [...]
M. HANEY ; A. S. WARD ; S. D. COMER ; C. L. HART ; R. W. FOLTIN ; M. W. FISCHMAN | 2001
Dans Psychopharmacology (Vol.155, n°2, May 2001) Article : PériodiqueRATIONALE: Symptoms of withdrawal after daily marijuana smoking include increased ratings of irritability and depression. Similar mood symptoms are reported by cigarette smokers during nicotine abstinence. OBJECTIVE: Given the successful use o[...]
Z. D. COOPER ; S. D. COMER ; M. HANEY | 2013
Dans Neuropsychopharmacology (Vol.38, n°10, September 2013) Article : PériodiqueRecent studies have demonstrated the therapeutic potential of cannabinoids to treat pain, yet none have compared the analgesic effectiveness of smoked marijuana to orally administered Δ9-tetrahydrocannabinol (THC; dronabinol). This randomized, p[...]
M. HANEY ; E. W. GUNDERSON ; RABKIN J. ; C. L. HART ; S. K. VOSBURG ; S. D. COMER ; R. W. FOLTIN | 2007
PériodiqueENGLISH : OBJECTIVES: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral dronabinol maintenance in HIV-p[...]
S. L. WALSH ; S. D. COMER ; M. R. LOFWALL ; B. VINCE ; N. LEVY-COOPERMAN ; D. KELSH ; M. A. COE ; J. D. JONES ; P. A. NUZZO ; F. TIBERG ; B. SHELDON ; S. KIM | 2017
Dans JAMA Psychiatry (Vol.74, n°9, September 2017) Article : PériodiqueImportance: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may be obviated by a sustained r[...]
P. ROUX ; L. FUGON ; J. D. JONES ; S. D. COMER | 2013
Dans American Journal on Addictions (Vol.22, n°6, November-December 2013) Article : PériodiqueBackground and Objectives: In heroin dependent individuals, the HIV epidemic has been controlled in countries where access to opioid maintenance treatment (OMT) and needle exchange programs (NEP) have been implemented. However, despite similar r[...]
J. NEALE ; C. BROWN ; A. N. C. CAMPBELL ; J. D. JONES ; V. E. METZ ; J. STRANG ; S. D. COMER | 2019
Dans Addiction (Vol.114, n°4, April 2019) Article : PériodiqueBACKGROUND AND AIMS: Providing take-home naloxone (THN) to people who use opioids is an increasingly common strategy for reversing opioid overdose. However, implementation is hindered by doubts regarding the ability of people who use opioids to [...]
P. ROUX ; C. TINDALL ; L. FUGON ; J. MURRAY ; S. K. VOSBURG ; P. SACCONE ; M. A. SULLIVAN ; J. M. MANUBAY ; Z. D. COOPER ; J. D. JONES ; R. W. FOLTIN ; S. D. COMER | 2012
Dans Addiction (Vol.107, n°3, March 2012) Article : PériodiqueAims: Research on drug dependence often involves the administration of drugs of abuse to experienced drug users under controlled laboratory conditions. The primary objective of this study was to assess whether participation in such research alte[...]
S. D. COMER ; E. D. COLLINS ; M. W. FISCHMAN | 2002
Dans Journal of Pharmacology and Experimental Therapeutics (Vol.301, n°1, April 2002) Article : PériodiqueSeveral sources indicate that intravenously administered buprenorphine may have significant abuse liability in humans. The present study evaluated the reinforcing effects of intravenously administered buprenorphine (0, 2, and 8 mg) in detoxified[...]
J. D. JONES ; A. CAMPBELL ; V. E. METZ ; S. D. COMER | 2017
Dans Addictive Behaviors (Vol.71, August 2017) Article : PériodiqueIntroduction: Some fear that distribution of naloxone to persons at risk of experiencing an opioid overdose may reduce the perceived negative consequences of drug use, leading to riskier patterns of use. This study assessed whether participation[...]![Pharmacotherapeutic strategies for treating cocaine use disorder - What do we have to offer? [Addiction Opinion and Debate]](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_83943.webp)
L. BRANDT ; T. CHAO ; S. D. COMER ; F. R. LEVIN | 2021
Dans Addiction (Vol.116, n°4, April 2021) Article : PériodiqueBACKGROUND: Cocaine use continues to be a significant public health problem world-wide. However, despite substantial research efforts, no pharmacotherapies are approved for the treatment of cocaine use disorder (CUD). ARGUMENT: Studies have id[...]
J. D. JONES ; S. MOGALI ; S. D. COMER | 2012
Dans Drug and Alcohol Dependence (Vol.125, n°1-2, September 2012) Article : PériodiqueThis paper reviews studies examining the pharmacological interactions and epidemiology of the combined use of opioids and benzodiazepines (BZDs). A search of English language publications from 1970 to 2012 was conducted using PubMed and PsycINFO[...]
G. K. HULSE ; R. J. TAIT ; S. D. COMER ; M. A. SULLIVAN ; I. G. JACOBS ; D. ARNOLD-REED | 2005
PériodiqueENGLISH : Background: Non-fatal overdoses represent a significant morbidity for regular heroin users. Naltrexone is an opioid antagonist capable of blocking the effects of heroin, thereby preventing accidental overdose. However, treatment with[...]
S. D. COMER ; E. D. COLLINS | 2002
Dans Journal of Pharmacology and Experimental Therapeutics (Vol.303, n°2, November 2002) Article : PériodiqueBuprenorphine is a partial μ-opioid agonist and κ-opioid antagonist currently under development as a maintenance medication for heroin dependence. Because of concerns about illicit diversion of buprenorphine, a combination tablet containing bupr[...]
FRANÇAIS : Les opioïdes sont bien caractérisés naturellement sur le plan pharmacologique, et sur la possibilité d'inhibition de leurs effets par des antagonistes tels que la naloxone ou la naltrexone, et sur la possibilité que ces inhibiteurs i[...]
